Procter & Gamble Health Limited — Important, 12-02-2025: Financial Result Updates

Consolidated financials for Procter & Gamble Health Limited reveal a solid performance for the quarter ended December 31, 2024, with total revenue from operations reaching ₹309.79 crore, marking a slight increase from ₹309.97 crore in the corresponding period of the previous year, representing a year-over-year growth of 2.28%. Revenue drivers include operational improvements and strategic market positioning.

Net profit for the period stood at ₹90.90 crore, up from ₹72.07 crore in the same quarter last year, translating to an Earnings Per Share (EPS) of ₹54.76, compared to ₹43.42 previously. Factors contributing to profitability include effective cost management, despite a marginal rise in operational costs which grew by 11% year-over-year to a total of ₹192.04 crore, driven largely by employee benefits and material costs.

The balance sheet reflects healthy liquidity with total assets of ₹870.15 crore, a notable rise from ₹794.36 crore. Cash and cash equivalents increased to ₹266.68 crore, showcasing effective cash management strategies.

Looking ahead, the company's focus on cost control and strategic market expansions appears promising as it navigates post-pandemic market dynamics. Overall, investor sentiment remains cautiously optimistic. Based on current performance and operational efficiencies, a 'hold' position seems advisable as the company seeks to leverage growth opportunities while managing risks effectively.